combinedID,comparedID,samplesize_treated,MeanofEffectvalue_treated,Meanofvaribility_treated,samplesize_control,MeanofEffectvalue_control,Meanofvaribility_control,Bibliography,Year,Species,Endpointname,Drug,UnitofDose,UnitofVariability,t,SE,Effectsize,UL,LL
1.1,1.1.1,12,28.8,16.86,12,29.42,24.05,"Aramwit, P.,Bunmee, P.,Supasyndh, O..  Effectiveness and tolerability of rosiglitazone on insulin resistance and body composition in nondiabetic Thai patients undergoing continuous ambulatory peritoneal dialysis: A 12-week pilot study. Current Therapeutic Research - Clinical and Experimental.  2009. 70:377-389",2009,Human,AST,Rosiglitazone/Avandia,mg,SD,2.073873068,23.86090544,-0.62,48.86448916,-50.10448916
100.1,100.1.1,5,0.038,0.156524758,10,0.038,0.006324555,"Egerod, F. L.,Brunner, N.,Svendsen, J. E.,Oleksiewicz, M. B..  PPAR alpha and PPAR gamma are co-expressed, functional and show positive interactions in the rat urinary bladder urothelium. Journal of Applied Toxicology.  2010. 30:151-162",2010,Rat,"Liver weight, relative",Rosiglitazone/Avandia,mg/kg,SD,2.160368656,0.171488506,0,0.370478393,-0.370478393
100.1,100.1.2,5,0.037,0.002236068,10,0.038,0.006324555,"Egerod, F. L.,Brunner, N.,Svendsen, J. E.,Oleksiewicz, M. B..  PPAR alpha and PPAR gamma are co-expressed, functional and show positive interactions in the rat urinary bladder urothelium. Journal of Applied Toxicology.  2010. 30:151-162",2010,Rat,"Liver weight, relative",Rosiglitazone/Avandia,mg/kg,SD,2.160368656,0.003782551,-0.001,0.007171705,-0.009171705
101.1,101.1.1,5,12.5,5.590169944,10,12.5,7.90569415,"Egerod, F. L.,Brunner, N.,Svendsen, J. E.,Oleksiewicz, M. B..  PPAR alpha and PPAR gamma are co-expressed, functional and show positive interactions in the rat urinary bladder urothelium. Journal of Applied Toxicology.  2010. 30:151-162",2010,Rat,"Liver weight, absolute",Rosiglitazone/Avandia,mg/kg,SD,2.160368656,7.104982001,0,15.34938042,-15.34938042
101.1,101.1.2,5,12,2.236067977,10,12.5,7.90569415,"Egerod, F. L.,Brunner, N.,Svendsen, J. E.,Oleksiewicz, M. B..  PPAR alpha and PPAR gamma are co-expressed, functional and show positive interactions in the rat urinary bladder urothelium. Journal of Applied Toxicology.  2010. 30:151-162",2010,Rat,"Liver weight, absolute",Rosiglitazone/Avandia,mg/kg,SD,2.160368656,4.356692465,-0.5,8.912061846,-9.912061846
108.1,108.1.1,8,14.3,0.848528137,8,19.45,2.121320344,"Jia, D. M.,Tabaru, A.,Akiyama, T.,Abe, S.,Otsuki, M..  Troglitazone prevents fatty changes of the liver in obese diabetic rats. J Gastroenterol Hepatol.  2000. 15:1183-91",2000,Rat,"Liver weight, absolute",Troglitazone/Rezulin,mg/100g,SD,2.144786688,1.35,-5.15,-2.254537971,-8.045462029
108.1,108.1.2,8,19.6,1.414213562,8,19.45,2.121320344,"Jia, D. M.,Tabaru, A.,Akiyama, T.,Abe, S.,Otsuki, M..  Troglitazone prevents fatty changes of the liver in obese diabetic rats. J Gastroenterol Hepatol.  2000. 15:1183-91",2000,Rat,"Liver weight, absolute",Troglitazone/Rezulin,mg/100g,SD,2.144786688,2.015564437,0.15,4.472955773,-4.172955773
108.1,108.1.3,8,13.1,1.697056275,8,19.45,2.121320344,"Jia, D. M.,Tabaru, A.,Akiyama, T.,Abe, S.,Otsuki, M..  Troglitazone prevents fatty changes of the liver in obese diabetic rats. J Gastroenterol Hepatol.  2000. 15:1183-91",2000,Rat,"Liver weight, absolute",Troglitazone/Rezulin,mg/100g,SD,2.144786688,2.366960076,-6.35,-1.273375539,-11.42662446
108.1,108.1.4,8,19.5,1.697056275,8,19.45,2.121320344,"Jia, D. M.,Tabaru, A.,Akiyama, T.,Abe, S.,Otsuki, M..  Troglitazone prevents fatty changes of the liver in obese diabetic rats. J Gastroenterol Hepatol.  2000. 15:1183-91",2000,Rat,"Liver weight, absolute",Troglitazone/Rezulin,mg/100g,SD,2.144786688,2.366960076,0.05,5.126624461,-5.026624461
109.1,109.1.1,8,25.9,0.565685425,8,31.1,3.676955262,"Jia, D. M.,Tabaru, A.,Akiyama, T.,Abe, S.,Otsuki, M..  Troglitazone prevents fatty changes of the liver in obese diabetic rats. J Gastroenterol Hepatol.  2000. 15:1183-91",2000,Rat,"Liver weight, relative",Troglitazone/Rezulin,mg/100g,SD,2.144786688,1.5,-5.2,-1.982819968,-8.417180032
109.1,109.1.2,8,27.6,1.414213562,8,31.1,3.676955262,"Jia, D. M.,Tabaru, A.,Akiyama, T.,Abe, S.,Otsuki, M..  Troglitazone prevents fatty changes of the liver in obese diabetic rats. J Gastroenterol Hepatol.  2000. 15:1183-91",2000,Rat,"Liver weight, relative",Troglitazone/Rezulin,mg/100g,SD,2.144786688,2.27815715,-3.5,1.386161128,-8.386161128
109.1,109.1.3,8,24.8,1.979898987,8,31.1,3.676955262,"Jia, D. M.,Tabaru, A.,Akiyama, T.,Abe, S.,Otsuki, M..  Troglitazone prevents fatty changes of the liver in obese diabetic rats. J Gastroenterol Hepatol.  2000. 15:1183-91",2000,Rat,"Liver weight, relative",Troglitazone/Rezulin,mg/100g,SD,2.144786688,2.924038303,-6.3,-0.028561572,-12.57143843
109.1,109.1.4,8,27.7,1.13137085,8,31.1,3.676955262,"Jia, D. M.,Tabaru, A.,Akiyama, T.,Abe, S.,Otsuki, M..  Troglitazone prevents fatty changes of the liver in obese diabetic rats. J Gastroenterol Hepatol.  2000. 15:1183-91",2000,Rat,"Liver weight, relative",Troglitazone/Rezulin,mg/100g,SD,2.144786688,1.98242276,-3.4,0.851873946,-7.651873946
110.1,110.1.1,8,76.4,7.353910524,8,83.35,14.8492424,"Jia, D. M.,Tabaru, A.,Akiyama, T.,Abe, S.,Otsuki, M..  Troglitazone prevents fatty changes of the liver in obese diabetic rats. J Gastroenterol Hepatol.  2000. 15:1183-91",2000,Rat,AST,Troglitazone/Rezulin,mg/100g,SD,2.144786688,11.05452396,-6.95,16.75959583,-30.65959583
110.1,110.1.2,8,69,42.70924958,8,83.35,14.8492424,"Jia, D. M.,Tabaru, A.,Akiyama, T.,Abe, S.,Otsuki, M..  Troglitazone prevents fatty changes of the liver in obese diabetic rats. J Gastroenterol Hepatol.  2000. 15:1183-91",2000,Rat,AST,Troglitazone/Rezulin,mg/100g,SD,2.144786688,56.7424224,-14.35,107.3503922,-136.0503922
110.1,110.1.3,8,82,5.656854249,8,83.35,14.8492424,"Jia, D. M.,Tabaru, A.,Akiyama, T.,Abe, S.,Otsuki, M..  Troglitazone prevents fatty changes of the liver in obese diabetic rats. J Gastroenterol Hepatol.  2000. 15:1183-91",2000,Rat,AST,Troglitazone/Rezulin,mg/100g,SD,2.144786688,9.141252649,-1.35,18.25603699,-20.95603699
110.1,110.1.4,8,52.6,9.050966799,8,83.35,14.8492424,"Jia, D. M.,Tabaru, A.,Akiyama, T.,Abe, S.,Otsuki, M..  Troglitazone prevents fatty changes of the liver in obese diabetic rats. J Gastroenterol Hepatol.  2000. 15:1183-91",2000,Rat,AST,Troglitazone/Rezulin,mg/100g,SD,2.144786688,13.07373321,-30.75,-2.709631054,-58.79036895
111.1,111.1.1,8,35.8,9.333809512,8,43.2,8.061017306,"Jia, D. M.,Tabaru, A.,Akiyama, T.,Abe, S.,Otsuki, M..  Troglitazone prevents fatty changes of the liver in obese diabetic rats. J Gastroenterol Hepatol.  2000. 15:1183-91",2000,Rat,ALT,Troglitazone/Rezulin,mg/100g,SD,2.144786688,12.67211506,-7.4,19.77898368,-34.57898368
111.1,111.1.2,8,35,7.353910524,8,43.2,8.061017306,"Jia, D. M.,Tabaru, A.,Akiyama, T.,Abe, S.,Otsuki, M..  Troglitazone prevents fatty changes of the liver in obese diabetic rats. J Gastroenterol Hepatol.  2000. 15:1183-91",2000,Rat,ALT,Troglitazone/Rezulin,mg/100g,SD,2.144786688,10.13718403,-8.2,13.54209735,-29.94209735
111.1,111.1.3,8,36,3.676955262,8,43.2,8.061017306,"Jia, D. M.,Tabaru, A.,Akiyama, T.,Abe, S.,Otsuki, M..  Troglitazone prevents fatty changes of the liver in obese diabetic rats. J Gastroenterol Hepatol.  2000. 15:1183-91",2000,Rat,ALT,Troglitazone/Rezulin,mg/100g,SD,2.144786688,5.637597006,-7.2,4.89144301,-19.29144301
111.1,111.1.4,8,36.2,10.74802307,8,43.2,8.061017306,"Jia, D. M.,Tabaru, A.,Akiyama, T.,Abe, S.,Otsuki, M..  Troglitazone prevents fatty changes of the liver in obese diabetic rats. J Gastroenterol Hepatol.  2000. 15:1183-91",2000,Rat,ALT,Troglitazone/Rezulin,mg/100g,SD,2.144786688,14.50112065,-7,24.10181052,-38.10181052
112.1,112.1.1,10,9.32,1.043551628,10,9.29,0.980306075,"Kakiuchi-Kiyota, S.,Arnold, L. L.,Yokohira, M.,Suzuki, S.,Pennington, K. L.,Cohen, S. M..  Evaluation of PPARgamma agonists on rodent endothelial cell proliferation. Toxicology.  2011. 287:91-8",2011,Rat,"Liver weight, absolute",Troglitazone/Rezulin,mg/kg,SD,2.10092204,1.433980474,0.03,3.042681183,-2.982681183
112.1,112.1.2,10,9.15,0.695701085,10,9.29,0.980306075,"Kakiuchi-Kiyota, S.,Arnold, L. L.,Yokohira, M.,Suzuki, S.,Pennington, K. L.,Cohen, S. M..  Evaluation of PPARgamma agonists on rodent endothelial cell proliferation. Toxicology.  2011. 287:91-8",2011,Rat,"Liver weight, absolute",Troglitazone/Rezulin,mg/kg,SD,2.10092204,0.983514108,-0.14,1.926286466,-2.206286466
113.1,113.1.1,10,35.35,1.612761607,10,36.89,2.624690458,"Kakiuchi-Kiyota, S.,Arnold, L. L.,Yokohira, M.,Suzuki, S.,Pennington, K. L.,Cohen, S. M..  Evaluation of PPARgamma agonists on rodent endothelial cell proliferation. Toxicology.  2011. 287:91-8",2011,Rat,"Liver weight, relative",Troglitazone/Rezulin,mg/kg,SD,2.10092204,2.317477076,-1.54,3.328838668,-6.408838668
113.1,113.1.2,10,36.01,2.276839915,10,36.89,2.624690458,"Kakiuchi-Kiyota, S.,Arnold, L. L.,Yokohira, M.,Suzuki, S.,Pennington, K. L.,Cohen, S. M..  Evaluation of PPARgamma agonists on rodent endothelial cell proliferation. Toxicology.  2011. 287:91-8",2011,Rat,"Liver weight, relative",Troglitazone/Rezulin,mg/kg,SD,2.10092204,3.165454154,-0.88,5.770372399,-7.530372399
114.1,114.1.1,4,0.375,0.092,4,0.33,0.052,"Kostrubsky, V. E.,Vore, M.,Kindt, E.,Burliegh, J.,Rogers, K.,Peter, G.,Altrogge, D.,Sinz, M. W..  The effect of troglitazone biliary excretion on metabolite distribution and cholestasis in transporter-deficient rats. Drug Metabolism and Disposition.  2001. 29:1561-1566",2001,Rat,Bilirubin (total),Troglitazone/Rezulin,mg/kg,SD,2.446911851,0.115637364,0.045,0.327954437,-0.237954437
114.1,114.1.2,4,0.23,0.048,4,0.33,0.052,"Kostrubsky, V. E.,Vore, M.,Kindt, E.,Burliegh, J.,Rogers, K.,Peter, G.,Altrogge, D.,Sinz, M. W..  The effect of troglitazone biliary excretion on metabolite distribution and cholestasis in transporter-deficient rats. Drug Metabolism and Disposition.  2001. 29:1561-1566",2001,Rat,Bilirubin (total),Troglitazone/Rezulin,mg/kg,SD,2.446911851,0.064280635,-0.1,0.057289047,-0.257289047
115.1,115.1.1,5,10.6,1,5,11,1.5,"Li, J.,Kaneko, T.,Wang, Y.,Qin, L. Q.,Wang, P. Y.,Sato, A..  Troglitazone enhances the hepatotoxicity of acetaminophen by inducing CYP3A in rats. Toxicology.  2002. 176:91-100",2002,Rat,ALT,Troglitazone/Rezulin,mg/kg,SD,2.306004135,1.431782106,-0.4,2.901695458,-3.701695458
115.1,115.1.2,5,11.8,1.9,5,11,1.5,"Li, J.,Kaneko, T.,Wang, Y.,Qin, L. Q.,Wang, P. Y.,Sato, A..  Troglitazone enhances the hepatotoxicity of acetaminophen by inducing CYP3A in rats. Toxicology.  2002. 176:91-100",2002,Rat,ALT,Troglitazone/Rezulin,mg/kg,SD,2.306004135,2.495195383,0.8,6.553930872,-4.953930872
116.1,116.1.1,5,51.3,11,5,48.8,4.1,"Li, J.,Kaneko, T.,Wang, Y.,Qin, L. Q.,Wang, P. Y.,Sato, A..  Troglitazone enhances the hepatotoxicity of acetaminophen by inducing CYP3A in rats. Toxicology.  2002. 176:91-100",2002,Rat,AST,Troglitazone/Rezulin,mg/kg,SD,2.306004135,14.03431509,2.5,34.86318863,-29.86318863
116.1,116.1.2,5,53.4,3.2,5,48.8,4.1,"Li, J.,Kaneko, T.,Wang, Y.,Qin, L. Q.,Wang, P. Y.,Sato, A..  Troglitazone enhances the hepatotoxicity of acetaminophen by inducing CYP3A in rats. Toxicology.  2002. 176:91-100",2002,Rat,AST,Troglitazone/Rezulin,mg/kg,SD,2.306004135,4.443647151,4.6,14.8470687,-5.647068705
117.1,117.1.1,10,77,15.85,10,108.33,10.11,"Liu, S.,Wu, H. J.,Zhang, Z. Q.,Chen, Q.,Liu, B.,Wu, J. P.,Zhu, L..  The ameliorating effect of rosiglitazone on experimental nonalcoholic steatohepatitis is associated with regulating adiponectin receptor expression in rats. Eur J Pharmacol.  2011. 650:384-9",2011,Rat,ALT,Rosiglitazone/Avandia,mg/kg,SD,2.10092204,21.50399289,-31.33,13.84821261,-76.50821261
118.1,118.1.1,10,78.3,25.64,10,164.33,33.54,"Liu, S.,Wu, H. J.,Zhang, Z. Q.,Chen, Q.,Liu, B.,Wu, J. P.,Zhu, L..  The ameliorating effect of rosiglitazone on experimental nonalcoholic steatohepatitis is associated with regulating adiponectin receptor expression in rats. Eur J Pharmacol.  2011. 650:384-9",2011,Rat,AST,Rosiglitazone/Avandia,mg/kg,SD,2.10092204,35.99764492,-86.03,-10.40175438,-161.6582456
120.1,120.1.1,10,86.8,25.64,10,91.11,19.63,"Liu, S.,Wu, H. J.,Zhang, Z. Q.,Chen, Q.,Liu, B.,Wu, J. P.,Zhu, L..  The ameliorating effect of rosiglitazone on experimental nonalcoholic steatohepatitis is associated with regulating adiponectin receptor expression in rats. Eur J Pharmacol.  2011. 650:384-9",2011,Rat,Gamma-glutamyl transferase (γGT),Rosiglitazone/Avandia,mg/kg,SD,2.10092204,34.95527099,-4.31,69.12829925,-77.74829925
122.1,122.1.1,6,45,7.348469228,6,42,75.93418203,"Meghani, N. M.,Barve, K.,Wackchaure, S.,Nandanwar, M. B.,Latad, S.,Mankani, H..  Toxicity assessment of clarithromycin in diabetic wistar rats treated with rosiglitazone. International Journal of Pharmaceutical Sciences and Research.  2012. 3:2623-2632",2012,Rat,ALT,Rosiglitazone/Avandia,mg/kg,SD,2.228138852,32.41913015,3,75.23432345,-69.23432345
123.1,123.1.1,6,190,29.39387691,6,145,110.2270384,"Meghani, N. M.,Barve, K.,Wackchaure, S.,Nandanwar, M. B.,Latad, S.,Mankani, H..  Toxicity assessment of clarithromycin in diabetic wistar rats treated with rosiglitazone. International Journal of Pharmaceutical Sciences and Research.  2012. 3:2623-2632",2012,Rat,ALP,Rosiglitazone/Avandia,mg/kg,SD,2.228138852,58.86425061,45,176.1577238,-86.15772378
124.1,124.1.1,6,160,24.49489743,6,175,29.39387691,"Meghani, N. M.,Barve, K.,Wackchaure, S.,Nandanwar, M. B.,Latad, S.,Mankani, H..  Toxicity assessment of clarithromycin in diabetic wistar rats treated with rosiglitazone. International Journal of Pharmaceutical Sciences and Research.  2012. 3:2623-2632",2012,Rat,AST,Rosiglitazone/Avandia,mg/kg,SD,2.228138852,33.82306905,-15,60.36249425,-90.36249425
129.1,129.1.1,5,60,3.6,9,54,7.2,"Spicker, J. S.,Pedersen, H. T.,Nielsen, H. B.,Brunak, S..  Analysis of cell death inducing compounds. Arch Toxicol.  2007. 81:803-11",2007,Rat,ALT,Rosiglitazone/Avandia,mg/kg,SD,2.17881283,5.184592559,6,17.29625678,-5.296256784
130.1,130.1.1,5,109,14,9,104,16,"Spicker, J. S.,Pedersen, H. T.,Nielsen, H. B.,Brunak, S..  Analysis of cell death inducing compounds. Arch Toxicol.  2007. 81:803-11",2007,Rat,AST,Rosiglitazone/Avandia,mg/kg,SD,2.17881283,17.23390285,5,42.54944863,-32.54944863
132.1,132.1.1,5,62.8,10.3,5,82.2,14.95,"Watanabe, T.,Furukawa, T.,Sharyo, S.,Ohashi, Y.,Yasuda, M.,Takaoka, M.,Manabe, S..  Effect of troglitazone on the liver of a Gunn rat model of genetic enzyme polymorphism. J Toxicol Sci.  2000. 25:423-31",2000,Rat,ALT,Troglitazone/Rezulin,mg/kg,SD,2.306004135,14.64392365,-19.4,14.3689485,-53.1689485
132.1,132.1.2,5,60.6,8.1,5,82.2,14.95,"Watanabe, T.,Furukawa, T.,Sharyo, S.,Ohashi, Y.,Yasuda, M.,Takaoka, M.,Manabe, S..  Effect of troglitazone on the liver of a Gunn rat model of genetic enzyme polymorphism. J Toxicol Sci.  2000. 25:423-31",2000,Rat,ALT,Troglitazone/Rezulin,mg/kg,SD,2.306004135,12.23423475,-21.6,6.612195932,-49.81219593
133.1,133.1.1,5,96.8,10.65,5,130.8,25.8,"Watanabe, T.,Furukawa, T.,Sharyo, S.,Ohashi, Y.,Yasuda, M.,Takaoka, M.,Manabe, S..  Effect of troglitazone on the liver of a Gunn rat model of genetic enzyme polymorphism. J Toxicol Sci.  2000. 25:423-31",2000,Rat,AST,Troglitazone/Rezulin,mg/kg,SD,2.306004135,17.7370798,-34,6.901779376,-74.90177938
133.1,133.1.2,5,85.7,6.35,5,130.8,25.8,"Watanabe, T.,Furukawa, T.,Sharyo, S.,Ohashi, Y.,Yasuda, M.,Takaoka, M.,Manabe, S..  Effect of troglitazone on the liver of a Gunn rat model of genetic enzyme polymorphism. J Toxicol Sci.  2000. 25:423-31",2000,Rat,AST,Troglitazone/Rezulin,mg/kg,SD,2.306004135,14.05859168,-45.1,-12.68082945,-77.51917055
134.1,134.1.1,5,922.7,81.55,5,816.8,88.8,"Watanabe, T.,Furukawa, T.,Sharyo, S.,Ohashi, Y.,Yasuda, M.,Takaoka, M.,Manabe, S..  Effect of troglitazone on the liver of a Gunn rat model of genetic enzyme polymorphism. J Toxicol Sci.  2000. 25:423-31",2000,Rat,ALP,Troglitazone/Rezulin,mg/kg,SD,2.306004135,110.53385,105.9,360.7915152,-148.9915152
134.1,134.1.2,5,949.2,47.4,5,816.8,88.8,"Watanabe, T.,Furukawa, T.,Sharyo, S.,Ohashi, Y.,Yasuda, M.,Takaoka, M.,Manabe, S..  Effect of troglitazone on the liver of a Gunn rat model of genetic enzyme polymorphism. J Toxicol Sci.  2000. 25:423-31",2000,Rat,ALP,Troglitazone/Rezulin,mg/kg,SD,2.306004135,71.91595094,132.4,298.2384803,-33.43848026
135.1,135.1.1,5,0.065,0.01,5,0.075,0.005,"Watanabe, T.,Furukawa, T.,Sharyo, S.,Ohashi, Y.,Yasuda, M.,Takaoka, M.,Manabe, S..  Effect of troglitazone on the liver of a Gunn rat model of genetic enzyme polymorphism. J Toxicol Sci.  2000. 25:423-31",2000,Rat,Bilirubin (total),Troglitazone/Rezulin,mg/kg,SD,2.306004135,0.012845233,-0.01,0.019621159,-0.039621159
135.1,135.1.2,5,0.07,0.005,5,0.075,0.005,"Watanabe, T.,Furukawa, T.,Sharyo, S.,Ohashi, Y.,Yasuda, M.,Takaoka, M.,Manabe, S..  Effect of troglitazone on the liver of a Gunn rat model of genetic enzyme polymorphism. J Toxicol Sci.  2000. 25:423-31",2000,Rat,Bilirubin (total),Troglitazone/Rezulin,mg/kg,SD,2.306004135,0.006708204,-0.005,0.010469146,-0.020469146
136.1,136.1.1,5,0.05,0.005,5,0.05,0.01,"Watanabe, T.,Furukawa, T.,Sharyo, S.,Ohashi, Y.,Yasuda, M.,Takaoka, M.,Manabe, S..  Effect of troglitazone on the liver of a Gunn rat model of genetic enzyme polymorphism. J Toxicol Sci.  2000. 25:423-31",2000,Rat,Bilirubin (direct),Troglitazone/Rezulin,mg/kg,SD,2.306004135,0.007745967,0,0.017862231,-0.017862231
136.1,136.1.2,5,0.045,0.01,5,0.05,0.01,"Watanabe, T.,Furukawa, T.,Sharyo, S.,Ohashi, Y.,Yasuda, M.,Takaoka, M.,Manabe, S..  Effect of troglitazone on the liver of a Gunn rat model of genetic enzyme polymorphism. J Toxicol Sci.  2000. 25:423-31",2000,Rat,Bilirubin (direct),Troglitazone/Rezulin,mg/kg,SD,2.306004135,0.013416408,-0.005,0.025938292,-0.035938292
138.1,138.1.1,6,9.11,7.642407997,6,9.21,5.756300896,"Yadav, H.,Jain, S.,Prasad, G. B.,Yadav, M..  Preventive effect of diabegon, a polyherbal preparation, during progression of diabetes induced by high-fructose feeding in rats. J Pharmacol Sci.  2007. 105:12-21",2007,Rat,"Liver weight, absolute",Rosiglitazone/Avandia,mg/kg,SD,2.228138852,10.14231236,-0.1,22.49848022,-22.69848022
139.1,139.1.1,6,5.89,5.192918255,6,7.01,5.560341716,"Yadav, H.,Jain, S.,Prasad, G. B.,Yadav, M..  Preventive effect of diabegon, a polyherbal preparation, during progression of diabetes induced by high-fructose feeding in rats. J Pharmacol Sci.  2007. 105:12-21",2007,Rat,SGOT,Rosiglitazone/Avandia,mg/kg,SD,2.228138852,7.07791636,-1.12,14.65058043,-16.89058043
140.1,140.1.1,6,1.03,0.318433667,6,0.99,0.293938769,"Yadav, H.,Jain, S.,Prasad, G. B.,Yadav, M..  Preventive effect of diabegon, a polyherbal preparation, during progression of diabetes induced by high-fructose feeding in rats. J Pharmacol Sci.  2007. 105:12-21",2007,Rat,Bilirubin (total),Rosiglitazone/Avandia,mg/kg,SD,2.228138852,0.428252262,0.04,0.994205504,-0.914205504
141.1,141.1.1,6,9.77,1.56,6,10.59,2.01,"Yadav, H.,Jain, S.,Yadav, M.,Sinha, P. R.,Prasad, G. B.,Marotta, F..  Epigenomic derangement of hepatic glucose metabolism by feeding of high fructose diet and its prevention by Rosiglitazone in rats. Dig Liver Dis.  2009. 41:500-8",2009,Rat,"Liver weight, absolute",Rosiglitazone/Avandia,g,SD,2.228138852,2.174706877,-0.82,4.025548884,-5.665548884
143.1,143.1.1,7.5,13.9,0.4,7.5,14.4,0.3,"Ye, J. M.,Iglesias, M. A.,Watson, D. G.,Ellis, B.,Wood, L.,Jensen, P. B.,Sorensen, R. V.,Larsen, P. J.,Cooney, G. J.,Wassermann, K.,Kraegen, E. W..  PPARalpha /gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly. Am J Physiol Endocrinol Metab.  2003. 284:E531-40",2003,Rat,"Liver weight, absolute",Rosiglitazone/Avandia,mg/kg,SD,2.160368656,0.53789714,-0.5,0.662056122,-1.662056122
15.1,15.1.1,19,36,10,19,41.5,17.9,"Mavandadi, A.,Gong, W. C..  Effects of troglitazone in Hispanic patients with type 2 diabetes mellitus. Current Therapeutic Research - Clinical and Experimental.  1999. 60:494-501",1999,Human,ALT,Troglitazone/Rezulin,mg,SD,2.028094001,14.36444807,-5.5,23.63245096,-34.63245096
15.1,15.1.2,19,35,8.1,19,41.5,17.9,"Mavandadi, A.,Gong, W. C..  Effects of troglitazone in Hispanic patients with type 2 diabetes mellitus. Current Therapeutic Research - Clinical and Experimental.  1999. 60:494-501",1999,Human,ALT,Troglitazone/Rezulin,mg,SD,2.028094001,11.8818083,-6.5,17.59742413,-30.59742413
16.1,16.1.1,19,22.3,7.5,19,24.5,12.8,"Mavandadi, A.,Gong, W. C..  Effects of troglitazone in Hispanic patients with type 2 diabetes mellitus. Current Therapeutic Research - Clinical and Experimental.  1999. 60:494-501",1999,Human,AST,Troglitazone/Rezulin,mg,SD,2.028094001,10.73322436,-2.2,19.56798795,-23.96798795
16.1,16.1.2,19,21.7,7,19,24.5,12.8,"Mavandadi, A.,Gong, W. C..  Effects of troglitazone in Hispanic patients with type 2 diabetes mellitus. Current Therapeutic Research - Clinical and Experimental.  1999. 60:494-501",1999,Human,AST,Troglitazone/Rezulin,mg,SD,2.028094001,10.07299673,-2.8,17.62898424,-23.22898424
2.1,2.1.1,12,24.5,12.25,12,23.42,18.25,"Aramwit, P.,Bunmee, P.,Supasyndh, O..  Effectiveness and tolerability of rosiglitazone on insulin resistance and body composition in nondiabetic Thai patients undergoing continuous ambulatory peritoneal dialysis: A 12-week pilot study. Current Therapeutic Research - Clinical and Experimental.  2009. 70:377-389",2009,Human,ALT,Rosiglitazone/Avandia,mg,SD,2.073873068,17.40315465,1.08,37.17193372,-35.01193372
26.1,26.1.1,6,27,9,6,27,6,"Beysen, C.,Murphy, E. J.,Nagaraja, H.,Decaris, M.,Riiff, T.,Fong, A.,Hellerstein, M. K.,Boyle, P. J..  A pilot study of the effects of pioglitazone and rosiglitazone on de novo lipogenesis in type 2 diabetes. Journal of Lipid Research.  2008. 49:2657-2663",2008,Human,AST,Rosiglitazone/Avandia,mg,SD,2.228138852,11.87434209,0,26.45768295,-26.45768295
27.1,27.1.1,6,30,10,6,36,10,"Beysen, C.,Murphy, E. J.,Nagaraja, H.,Decaris, M.,Riiff, T.,Fong, A.,Hellerstein, M. K.,Boyle, P. J..  A pilot study of the effects of pioglitazone and rosiglitazone on de novo lipogenesis in type 2 diabetes. Journal of Lipid Research.  2008. 49:2657-2663",2008,Human,ALT,Rosiglitazone/Avandia,mg,SD,2.228138852,13.54006401,-6,24.16914267,-36.16914267
33.1,33.1.1,628,29,28,628,22,9,"Chalasani, N.,Teal, E.,Hall, S. D..  Effect of rosiglitazone on serum liver biochemistries in diabetic patients with normal and elevated baseline liver enzymes. Am J Gastroenterol.  2005. 100:1317-21",2005,Human,AST,Rosiglitazone/Avandia,mg/day,SD,1.961857544,39.56807003,7,84.62691669,-70.62691669
34.1,34.1.1,628,26,23,628,24,11,"Chalasani, N.,Teal, E.,Hall, S. D..  Effect of rosiglitazone on serum liver biochemistries in diabetic patients with normal and elevated baseline liver enzymes. Am J Gastroenterol.  2005. 100:1317-21",2005,Human,ALT,Rosiglitazone/Avandia,mg/day,SD,1.961857544,32.5039684,2,65.76815562,-61.76815562
35.1,35.1.1,628,0.5,0.6,628,0.4,0.2,"Chalasani, N.,Teal, E.,Hall, S. D..  Effect of rosiglitazone on serum liver biochemistries in diabetic patients with normal and elevated baseline liver enzymes. Am J Gastroenterol.  2005. 100:1317-21",2005,Human,Bilirubin (free),Rosiglitazone/Avandia,mg/day,SD,1.961857544,0.84788985,0.1,1.763439098,-1.563439098
39.1,39.1.1,20,22.3,2.1,20,18.9,2.7,"Dereli, D.,Dereli, T.,Bayraktar, F.,Ozgen, A. G.,Yilmaz, C..  Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease. Endocr J.  2005. 52:299-308",2005,Human,AST,Rosiglitazone/Avandia,mg/day,SD,2.024394164,2.956940987,3.4,9.386014077,-2.586014077
39.1,39.1.2,20,21.6,2.4,20,18.9,2.7,"Dereli, D.,Dereli, T.,Bayraktar, F.,Ozgen, A. G.,Yilmaz, C..  Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease. Endocr J.  2005. 52:299-308",2005,Human,AST,Rosiglitazone/Avandia,mg/day,SD,2.024394164,3.362811324,2.7,9.507655618,-4.107655618
39.2,39.2.1,20,22.1,2.3,20,21.4,2.7,"Dereli, D.,Dereli, T.,Bayraktar, F.,Ozgen, A. G.,Yilmaz, C..  Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease. Endocr J.  2005. 52:299-308",2005,Human,AST,Rosiglitazone/Avandia,mg/day,SD,2.024394164,3.227305378,0.7,7.233338171,-5.833338171
39.2,39.2.2,20,22.4,2.1,20,21.4,2.7,"Dereli, D.,Dereli, T.,Bayraktar, F.,Ozgen, A. G.,Yilmaz, C..  Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease. Endocr J.  2005. 52:299-308",2005,Human,AST,Rosiglitazone/Avandia,mg/day,SD,2.024394164,2.956940987,1,6.986014077,-4.986014077
40.1,40.1.1,20,18.5,2.4,20,18.9,2.7,"Dereli, D.,Dereli, T.,Bayraktar, F.,Ozgen, A. G.,Yilmaz, C..  Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease. Endocr J.  2005. 52:299-308",2005,Human,ALT,Rosiglitazone/Avandia,mg/day,SD,2.024394164,3.362811324,-0.4,6.407655618,-7.207655618
40.1,40.1.2,20,19.1,1.9,20,18.9,2.7,"Dereli, D.,Dereli, T.,Bayraktar, F.,Ozgen, A. G.,Yilmaz, C..  Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease. Endocr J.  2005. 52:299-308",2005,Human,ALT,Rosiglitazone/Avandia,mg/day,SD,2.024394164,2.687656972,0.2,5.640877089,-5.240877089
40.2,40.2.1,20,19.3,1.5,20,18.6,2.9,"Dereli, D.,Dereli, T.,Bayraktar, F.,Ozgen, A. G.,Yilmaz, C..  Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease. Endocr J.  2005. 52:299-308",2005,Human,ALT,Rosiglitazone/Avandia,mg/day,SD,2.024394164,2.166910243,0.7,5.086680449,-3.686680449
40.2,40.2.2,20,19.6,1.9,20,18.6,2.9,"Dereli, D.,Dereli, T.,Bayraktar, F.,Ozgen, A. G.,Yilmaz, C..  Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease. Endocr J.  2005. 52:299-308",2005,Human,ALT,Rosiglitazone/Avandia,mg/day,SD,2.024394164,2.698054855,1,6.461926502,-4.461926502
45.1,45.1.1,8,40.4,3.39411255,8,34.9,5.656854249,"Anandharajan, R.,Sayyed, S. G.,Doshi, L. S.,Dixit, P.,Chandak, P. G.,Dixit, A. V.,Brahma, M. K.,Deshmukh, N. J.,Gupte, R.,Damre, A.,Suthar, J.,Padigaru, M.,Sharma, S. D.,Nemmani, K. V..  18F9 (4-(3,6-bis (ethoxycarbonyl)-4,5,6,7-tetrahydrothieno (2,3-c) pyridin-2-ylamino)-4-oxobutanoic acid) enhances insulin-mediated glucose uptake in vitro and exhibits antidiabetic activity in vivo in db/db mice. Metabolism.  2009. 58:1503-16",2009,Mouse,"liver weight, relative",Rosiglitazone/Avandia,mg/kg,SD,2.144786688,4.915282291,5.5,16.04223203,-5.042232025
46.1,46.1.1,8,59.3,26.87005769,8,36.1,14.99066376,"Anandharajan, R.,Sayyed, S. G.,Doshi, L. S.,Dixit, P.,Chandak, P. G.,Dixit, A. V.,Brahma, M. K.,Deshmukh, N. J.,Gupte, R.,Damre, A.,Suthar, J.,Padigaru, M.,Sharma, S. D.,Nemmani, K. V..  18F9 (4-(3,6-bis (ethoxycarbonyl)-4,5,6,7-tetrahydrothieno (2,3-c) pyridin-2-ylamino)-4-oxobutanoic acid) enhances insulin-mediated glucose uptake in vitro and exhibits antidiabetic activity in vivo in db/db mice. Metabolism.  2009. 58:1503-16",2009,Mouse,ALT,Rosiglitazone/Avandia,mg/kg,SD,2.144786688,35.93869781,23.2,100.2808406,-53.88084064
47.1,47.1.1,8,91.1,41.01219331,8,99.5,37.61808076,"Anandharajan, R.,Sayyed, S. G.,Doshi, L. S.,Dixit, P.,Chandak, P. G.,Dixit, A. V.,Brahma, M. K.,Deshmukh, N. J.,Gupte, R.,Damre, A.,Suthar, J.,Padigaru, M.,Sharma, S. D.,Nemmani, K. V..  18F9 (4-(3,6-bis (ethoxycarbonyl)-4,5,6,7-tetrahydrothieno (2,3-c) pyridin-2-ylamino)-4-oxobutanoic acid) enhances insulin-mediated glucose uptake in vitro and exhibits antidiabetic activity in vivo in db/db mice. Metabolism.  2009. 58:1503-16",2009,Mouse,AST,Rosiglitazone/Avandia,mg/kg,SD,2.144786688,55.86045113,-8.4,111.408752,-128.208752
59.1,59.1.1,8,145,82.02438662,8,87,28.28427125,"Kus, V.,Flachs, P.,Kuda, O.,Bardova, K.,Janovska, P.,Svobodova, M.,Jilkova, Z. M.,Rossmeisl, M.,Wang-Sattler, R.,Yu, Z.,Illig, T.,Kopecky, J..  Unmasking differential effects of rosiglitazone and pioglitazone in the combination treatment with n-3 fatty acids in mice fed a high-fat diet. PLoS One.  2011. 6:e27126",2011,Mouse,Trialylglycerol,Rosiglitazone/Avandia,mg/kg/diet,SD,2.144786688,108.9678852,58,291.7128695,-175.7128695
61.1,61.1.1,5.5,2.78,0.469041576,5.5,2.53,0.39868534,"Otake, K.,Azukizawa, S.,Fukui, M.,Shibabayashi, M.,Kamemoto, H.,Miike, T.,Kunishiro, K.,Kasai, M.,Shirahase, H..  A novel series of (S)-2,7-substituted-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids: peroxisome proliferator-activated receptor alpha/gamma dual agonists with protein-tyrosine phosphatase 1B inhibitory activity. Chem Pharm Bull (Tokyo).  2011. 59:1233-42",2011,Mouse,"Liver weight, absolute",Rosiglitazone/Avandia,mg/kg,SD,2.262157163,0.623618473,0.25,1.660722996,-1.160722996
61.1,61.1.2,5.5,2.76,0.633206128,5.5,2.53,0.39868534,"Otake, K.,Azukizawa, S.,Fukui, M.,Shibabayashi, M.,Kamemoto, H.,Miike, T.,Kunishiro, K.,Kasai, M.,Shirahase, H..  A novel series of (S)-2,7-substituted-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids: peroxisome proliferator-activated receptor alpha/gamma dual agonists with protein-tyrosine phosphatase 1B inhibitory activity. Chem Pharm Bull (Tokyo).  2011. 59:1233-42",2011,Mouse,"Liver weight, absolute",Rosiglitazone/Avandia,mg/kg,SD,2.262157163,0.827647268,0.23,2.102268195,-1.642268195
7.1,7.1.1,72,18.6,4.3,72,19.2,5.4,"Chiang, C. K.,Ho, T. I.,Peng, Y. S.,Hsu, S. P.,Pai, M. F.,Yang, S. Y.,Hung, K. Y.,Wu, K. D..  Rosiglitazone in diabetes control in hemodialysis patients with and without viral hepatitis infection: effectiveness and side effects. Diabetes Care.  2007. 30:3-7",2007,Human,AST,Rosiglitazone/Avandia,IU/L,SD,1.976810994,6.072181559,-0.6,11.40355526,-12.60355526
70.1,70.1.1,6,152.57,12.24,6,71.54,6.56,"Sundaresan, A.,Radhiga, T.,Pugalendi, K. V..  Effect of ursolic acid and Rosiglitazone combination on hepatic lipid accumulation in high fat diet-fed C57BL/6J mice. Eur J Pharmacol.  2014. 741:297-303",2014,Mouse,AST,Rosiglitazone/Avandia,mg/kg,SD,2.228138852,16.02711037,81.03,116.7406273,45.31937271
70.1,70.1.2,6,128.45,11.01,6,71.54,6.56,"Sundaresan, A.,Radhiga, T.,Pugalendi, K. V..  Effect of ursolic acid and Rosiglitazone combination on hepatic lipid accumulation in high fat diet-fed C57BL/6J mice. Eur J Pharmacol.  2014. 741:297-303",2014,Mouse,AST,Rosiglitazone/Avandia,mg/kg,SD,2.228138852,14.46394713,56.91,89.13768256,24.68231744
71.1,71.1.1,6,96.85,9.55,6,28.25,2.48,"Sundaresan, A.,Radhiga, T.,Pugalendi, K. V..  Effect of ursolic acid and Rosiglitazone combination on hepatic lipid accumulation in high fat diet-fed C57BL/6J mice. Eur J Pharmacol.  2014. 741:297-303",2014,Mouse,ALT,Rosiglitazone/Avandia,mg/kg,SD,2.228138852,12.37049851,68.6,96.16318834,41.03681166
71.1,71.1.2,6,61.57,5.2,6,28.25,2.48,"Sundaresan, A.,Radhiga, T.,Pugalendi, K. V..  Effect of ursolic acid and Rosiglitazone combination on hepatic lipid accumulation in high fat diet-fed C57BL/6J mice. Eur J Pharmacol.  2014. 741:297-303",2014,Mouse,ALT,Rosiglitazone/Avandia,mg/kg,SD,2.228138852,6.789089286,33.32,48.44703361,18.19296639
75.1,75.1.1,4,605,141.2,4,987,187.5,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,ALP,Troglitazone/Rezulin,mg/kg,SD,2.446911851,196.7110127,-382,99.33450812,-863.3345081
75.1,75.1.2,4,927,152,4,987,187.5,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,ALP,Troglitazone/Rezulin,mg/kg,SD,2.446911851,208.434792,-60,450.0215626,-570.0215626
75.1,75.1.3,4,745,174.3,4,987,187.5,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,ALP,Troglitazone/Rezulin,mg/kg,SD,2.446911851,233.1518765,-242,328.5020896,-812.5020896
75.1,75.1.4,4,738,194.9,4,987,187.5,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,ALP,Troglitazone/Rezulin,mg/kg,SD,2.446911851,256.4528758,-249,378.517581,-876.517581
75.2,75.2.1,4,449,76,4,816,104.3,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,ALP,Troglitazone/Rezulin,mg/kg,SD,2.446911851,106.6940603,-367,-105.9290394,-628.0709606
75.2,75.2.2,4,610,150,4,816,104.3,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,ALP,Troglitazone/Rezulin,mg/kg,SD,2.446911851,190.9702136,-206,261.287279,-673.287279
75.2,75.2.3,4,521,102.9,4,816,104.3,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,ALP,Troglitazone/Rezulin,mg/kg,SD,2.446911851,136.3900198,-295,38.73435582,-628.7343558
75.2,75.2.4,4,503,85.3,4,816,104.3,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,ALP,Troglitazone/Rezulin,mg/kg,SD,2.446911851,116.7636823,-313,-27.28956204,-598.710438
75.3,75.3.1,4,433,33.5,4,846,195.7,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,ALP,Troglitazone/Rezulin,mg/kg,SD,2.446911851,106.1037111,-413,-153.373572,-672.626428
75.3,75.3.2,4,643,87.7,4,846,195.7,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,ALP,Troglitazone/Rezulin,mg/kg,SD,2.446911851,145.2981676,-203,152.5318082,-558.5318082
75.3,75.3.3,4,522,42.5,4,846,195.7,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,ALP,Troglitazone/Rezulin,mg/kg,SD,2.446911851,110.8331967,-324,-52.80093739,-595.1990626
75.3,75.3.4,4,450,30.1,4,846,195.7,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,ALP,Troglitazone/Rezulin,mg/kg,SD,2.446911851,104.5640354,-396,-140.1410226,-651.8589774
76.1,76.1.1,4,114.43,16.9195,4,69.74,10.5665,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,"Liver weight, absolute",Troglitazone/Rezulin,mg/kg,SD,2.446911851,21.38497021,44.69,97.01713705,-7.637137046
76.1,76.1.2,4,104.795,15.66,4,69.74,10.5665,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,"Liver weight, absolute",Troglitazone/Rezulin,mg/kg,SD,2.446911851,19.89387168,35.055,83.73355039,-13.62355039
76.1,76.1.3,4,105.66,8.539,4,69.74,10.5665,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,"Liver weight, absolute",Troglitazone/Rezulin,mg/kg,SD,2.446911851,11.71684736,35.92,64.59009266,7.249907336
77.1,77.1.1,4,54.06,6.058,4,31.69,4.6615,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,"Liver weight, relative",Troglitazone/Rezulin,mg/kg,SD,2.446911851,7.77698152,22.37,41.39958825,3.340411753
77.1,77.1.2,4,49.505,11.2,4,31.69,4.6615,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,"Liver weight, relative",Troglitazone/Rezulin,mg/kg,SD,2.446911851,13.91374844,17.815,51.86071594,-16.23071594
77.1,77.1.3,4,48.87,2.5235,4,31.69,4.6615,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,"Liver weight, relative",Troglitazone/Rezulin,mg/kg,SD,2.446911851,3.870978421,17.18,26.65194297,7.708057026
79.1,79.1.1,4,64,21.95,4,55,12.55,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,ALT,Troglitazone/Rezulin,mg/kg,SD,2.446911851,27.60578517,9,76.5489229,-58.5489229
79.1,79.1.2,4,58,16.1,4,55,12.55,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,ALT,Troglitazone/Rezulin,mg/kg,SD,2.446911851,20.69276746,3,53.63337792,-47.63337792
79.1,79.1.3,4,57.5,15,4,55,12.55,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,ALT,Troglitazone/Rezulin,mg/kg,SD,2.446911851,19.41328476,2.5,50.00259654,-45.00259654
79.1,79.1.4,4,55,17.9,4,55,12.55,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,ALT,Troglitazone/Rezulin,mg/kg,SD,2.446911851,22.80330294,0,55.79767221,-55.79767221
79.2,79.2.1,4,43,12.3,4,37.5,8.2,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,ALT,Troglitazone/Rezulin,mg/kg,SD,2.446911851,15.61233487,5.5,43.70200721,-32.70200721
79.2,79.2.2,4,41.5,7.5,4,37.5,8.2,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,ALT,Troglitazone/Rezulin,mg/kg,SD,2.446911851,10.0590755,4,28.61367106,-20.61367106
79.2,79.2.3,4,46,8.6,4,37.5,8.2,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,ALT,Troglitazone/Rezulin,mg/kg,SD,2.446911851,11.30265456,8.5,36.15659938,-19.15659938
79.2,79.2.4,4,42.5,10.7,4,37.5,8.2,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,ALT,Troglitazone/Rezulin,mg/kg,SD,2.446911851,13.73116892,5,38.59895997,-28.59895997
79.3,79.3.1,4,40.5,10,4,45,13.2,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,ALT,Troglitazone/Rezulin,mg/kg,SD,2.446911851,13.91258423,-4.5,29.54286724,-38.54286724
79.3,79.3.2,4,40,11.45,4,45,13.2,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,ALT,Troglitazone/Rezulin,mg/kg,SD,2.446911851,15.4988306,-5,32.92427228,-42.92427228
79.3,79.3.3,4,42.5,10.05,4,45,13.2,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,ALT,Troglitazone/Rezulin,mg/kg,SD,2.446911851,13.96652247,-2.5,31.67484936,-36.67484936
79.3,79.3.4,4,41.5,10.05,4,45,13.2,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,ALT,Troglitazone/Rezulin,mg/kg,SD,2.446911851,13.96652247,-3.5,30.67484936,-37.67484936
79.4,79.4.1,4,46,9.2,4,52,11.55,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,ALT,Troglitazone/Rezulin,mg/kg,SD,2.446911851,12.66138322,-6,24.98128865,-36.98128865
79.4,79.4.2,4,40,15.25,4,52,11.55,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,ALT,Troglitazone/Rezulin,mg/kg,SD,2.446911851,19.5497922,-12,35.83661822,-59.83661822
79.4,79.4.3,4,47,18.8,4,52,11.55,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,ALT,Troglitazone/Rezulin,mg/kg,SD,2.446911851,23.73837874,-5,53.08572026,-63.08572026
79.4,79.4.4,4,39,17.45,4,52,11.55,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,ALT,Troglitazone/Rezulin,mg/kg,SD,2.446911851,22.13830109,-13,41.17047129,-67.17047129
79.4,79.4.5,4,39.5,14.15,4,52,11.55,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,ALT,Troglitazone/Rezulin,mg/kg,SD,2.446911851,18.26702973,-12.5,32.19781152,-57.19781152
8.1,8.1.1,72,11.2,5.7,72,13.4,4.8,"Chiang, C. K.,Ho, T. I.,Peng, Y. S.,Hsu, S. P.,Pai, M. F.,Yang, S. Y.,Hung, K. Y.,Wu, K. D..  Rosiglitazone in diabetes control in hemodialysis patients with and without viral hepatitis infection: effectiveness and side effects. Diabetes Care.  2007. 30:3-7",2007,Human,ALT,Rosiglitazone/Avandia,IU/L,SD,1.976810994,8.024805294,-2.2,13.66352333,-18.06352333
80.1,80.1.1,4,0.65,0.185,4,0.45,0.225,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,Bilirubin (total),Troglitazone/Rezulin,mg/kg,SD,2.446911851,0.25296986,0.2,0.818994948,-0.418994948
80.1,80.1.2,4,0.4,0.23,4,0.45,0.225,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,Bilirubin (total),Troglitazone/Rezulin,mg/kg,SD,2.446911851,0.30332532,-0.05,0.692210321,-0.792210321
80.1,80.1.3,4,0.5,0.133333333,4,0.45,0.225,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,Bilirubin (total),Troglitazone/Rezulin,mg/kg,SD,2.446911851,0.198300067,0.05,0.535222785,-0.435222785
80.1,80.1.4,4,0.5,0.16,4,0.45,0.225,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,Bilirubin (total),Troglitazone/Rezulin,mg/kg,SD,2.446911851,0.225956301,0.05,0.602895151,-0.502895151
80.2,80.2.1,4,0.3,0.05,4,0.35,0.14,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,Bilirubin (total),Troglitazone/Rezulin,mg/kg,SD,2.446911851,0.093005376,-0.05,0.177575957,-0.277575957
80.2,80.2.2,4,0.1,0,4,0.35,0.14,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,Bilirubin (total),Troglitazone/Rezulin,mg/kg,SD,2.446911851,0.07,-0.25,-0.07871617,-0.42128383
80.2,80.2.3,4,0.3,0.15,4,0.35,0.14,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,Bilirubin (total),Troglitazone/Rezulin,mg/kg,SD,2.446911851,0.196596033,-0.05,0.431053162,-0.531053162
80.2,80.2.4,4,0.1,0.025,4,0.35,0.14,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,Bilirubin (total),Troglitazone/Rezulin,mg/kg,SD,2.446911851,0.076403534,-0.25,-0.063047287,-0.436952713
80.3,80.3.1,4,0.3,0.07,4,0.3,0.075,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,Bilirubin (total),Troglitazone/Rezulin,mg/kg,SD,2.446911851,0.093574836,0,0.228969376,-0.228969376
80.3,80.3.2,4,0.1,0,4,0.3,0.075,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,Bilirubin (total),Troglitazone/Rezulin,mg/kg,SD,2.446911851,0.0375,-0.2,-0.108240806,-0.291759194
80.3,80.3.3,4,0.25,0.145,4,0.3,0.075,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,Bilirubin (total),Troglitazone/Rezulin,mg/kg,SD,2.446911851,0.181504132,-0.05,0.394124612,-0.494124612
80.3,80.3.4,4,0.15,0.05,4,0.3,0.075,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,Bilirubin (total),Troglitazone/Rezulin,mg/kg,SD,2.446911851,0.071807033,-0.15,0.02570548,-0.32570548
80.4,80.4.1,4,0.4,0.04,4,0.25,0.15,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,Bilirubin (total),Troglitazone/Rezulin,mg/kg,SD,2.446911851,0.089582364,0.15,0.369200149,-0.069200149
80.4,80.4.2,4,0.1,0,4,0.25,0.15,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,Bilirubin (total),Troglitazone/Rezulin,mg/kg,SD,2.446911851,0.075,-0.15,0.033518389,-0.333518389
80.4,80.4.3,4,0.25,0.115,4,0.25,0.15,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,Bilirubin (total),Troglitazone/Rezulin,mg/kg,SD,2.446911851,0.159569734,0,0.390453073,-0.390453073
80.4,80.4.4,4,0.15,0.04,4,0.25,0.15,"Rothwell, C.,McGuire, E. J.,Altrogge, D. M.,Masuda, H.,de la Iglesia, F. A..  Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J Toxicol Sci.  2002. 27:35-47",2002,Non-human primate,Bilirubin (total),Troglitazone/Rezulin,mg/kg,SD,2.446911851,0.089582364,-0.1,0.119200149,-0.319200149
81.1,81.1.1,8,35.3,1.979898987,8,32,4.242640687,"Anandharajan, R.,Sayyed, S. G.,Doshi, L. S.,Dixit, P.,Chandak, P. G.,Dixit, A. V.,Brahma, M. K.,Deshmukh, N. J.,Gupte, R.,Damre, A.,Suthar, J.,Padigaru, M.,Sharma, S. D.,Nemmani, K. V..  18F9 (4-(3,6-bis (ethoxycarbonyl)-4,5,6,7-tetrahydrothieno (2,3-c) pyridin-2-ylamino)-4-oxobutanoic acid) enhances insulin-mediated glucose uptake in vitro and exhibits antidiabetic activity in vivo in db/db mice. Metabolism.  2009. 58:1503-16",2009,Rat,"liver weight, relative",Rosiglitazone/Avandia,mg/kg,SD,2.144786688,3.018277655,3.3,9.773561734,-3.173561734
82.1,82.1.1,8,77.2,33.09259736,8,70.2,12.72792206,"Anandharajan, R.,Sayyed, S. G.,Doshi, L. S.,Dixit, P.,Chandak, P. G.,Dixit, A. V.,Brahma, M. K.,Deshmukh, N. J.,Gupte, R.,Damre, A.,Suthar, J.,Padigaru, M.,Sharma, S. D.,Nemmani, K. V..  18F9 (4-(3,6-bis (ethoxycarbonyl)-4,5,6,7-tetrahydrothieno (2,3-c) pyridin-2-ylamino)-4-oxobutanoic acid) enhances insulin-mediated glucose uptake in vitro and exhibits antidiabetic activity in vivo in db/db mice. Metabolism.  2009. 58:1503-16",2009,Rat,AST,Rosiglitazone/Avandia,mg/kg,SD,2.144786688,44.00806744,7,101.3879172,-87.38791721
83.1,83.1.1,8,41.6,18.95046174,8,40.4,7.353910524,"Anandharajan, R.,Sayyed, S. G.,Doshi, L. S.,Dixit, P.,Chandak, P. G.,Dixit, A. V.,Brahma, M. K.,Deshmukh, N. J.,Gupte, R.,Damre, A.,Suthar, J.,Padigaru, M.,Sharma, S. D.,Nemmani, K. V..  18F9 (4-(3,6-bis (ethoxycarbonyl)-4,5,6,7-tetrahydrothieno (2,3-c) pyridin-2-ylamino)-4-oxobutanoic acid) enhances insulin-mediated glucose uptake in vitro and exhibits antidiabetic activity in vivo in db/db mice. Metabolism.  2009. 58:1503-16",2009,Rat,ALT,Rosiglitazone/Avandia,mg/kg,SD,2.144786688,25.20357118,1.2,55.25628395,-52.85628395
9.1,9.1.1,72,79,9.4,72,75,8.6,"Chiang, C. K.,Ho, T. I.,Peng, Y. S.,Hsu, S. P.,Pai, M. F.,Yang, S. Y.,Hung, K. Y.,Wu, K. D..  Rosiglitazone in diabetes control in hemodialysis patients with and without viral hepatitis infection: effectiveness and side effects. Diabetes Care.  2007. 30:3-7",2007,Human,ALP,Rosiglitazone/Avandia,IU/L,SD,1.976810994,13.23981789,4,30.17261756,-22.17261756
94.1,94.1.1,3,256,32.90896534,3,45,2.771281292,"Dadarkar, S. S.,Fonseca, L. C.,Mishra, P. B.,Lobo, A. S.,Doshi, L. S.,Dagia, N. M.,Rangasamy, A. K.,Padigaru, M..  Phenotypic and genotypic assessment of concomitant drug-induced toxic effects in liver, kidney and blood. J Appl Toxicol.  2011. 31:117-30",2011,Rat,AST,Rosiglitazone/Avandia,mg/kg,SD,2.776445105,38.03366929,211,316.5983949,105.4016051
95.1,95.1.1,3,58,5.196152423,3,32,8.660254038,"Dadarkar, S. S.,Fonseca, L. C.,Mishra, P. B.,Lobo, A. S.,Doshi, L. S.,Dagia, N. M.,Rangasamy, A. K.,Padigaru, M..  Phenotypic and genotypic assessment of concomitant drug-induced toxic effects in liver, kidney and blood. J Appl Toxicol.  2011. 31:117-30",2011,Rat,ALT,Rosiglitazone/Avandia,mg/kg,SD,2.776445105,7.810249676,26,47.68472948,4.315270517
96.1,96.1.1,3,10.5,0.519615242,3,13.4,3.117691454,"Dadarkar, S. S.,Fonseca, L. C.,Mishra, P. B.,Lobo, A. S.,Doshi, L. S.,Dagia, N. M.,Rangasamy, A. K.,Padigaru, M..  Phenotypic and genotypic assessment of concomitant drug-induced toxic effects in liver, kidney and blood. J Appl Toxicol.  2011. 31:117-30",2011,Rat,Albumin,Rosiglitazone/Avandia,mg/kg,SD,2.776445105,1.897366596,-2.9,2.367934199,-8.167934199
97.1,97.1.1,3,34.9,0.866025404,3,37.8,1.905255888,"Dadarkar, S. S.,Fonseca, L. C.,Mishra, P. B.,Lobo, A. S.,Doshi, L. S.,Dagia, N. M.,Rangasamy, A. K.,Padigaru, M..  Phenotypic and genotypic assessment of concomitant drug-induced toxic effects in liver, kidney and blood. J Appl Toxicol.  2011. 31:117-30",2011,Rat,Bilirubin (total),Rosiglitazone/Avandia,mg/kg,SD,2.776445105,1.486606875,-2.9,1.227482381,-7.027482381
98.1,98.1.1,3,4,0.346410162,3,3.36,0.173205081,"Dadarkar, S. S.,Fonseca, L. C.,Mishra, P. B.,Lobo, A. S.,Doshi, L. S.,Dagia, N. M.,Rangasamy, A. K.,Padigaru, M..  Phenotypic and genotypic assessment of concomitant drug-induced toxic effects in liver, kidney and blood. J Appl Toxicol.  2011. 31:117-30",2011,Rat,"Liver weight, relative",Rosiglitazone/Avandia,mg/kg,SD,2.776445105,0.412310563,0.64,1.784757643,-0.504757643
